Platinum-resistant Recurrent Clear Cell Ovarian Cancer
1 clinical trials · Condition
◉ Watch Platinum-resistant Recurrent Clear Cell Ovarian Cancer
| Record | Firm | Date |
|---|---|---|
| Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. (NCT05130515) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-12-15 |
Track Platinum-resistant Recurrent Clear Cell Ovarian Cancer automatically
Every clearance here is in the API, with alerts when new ones post.